ALX Oncology upgraded by Jefferies with a new price target
$ALXO
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2025 | $4.00 | Buy | Jefferies |
| 3/6/2025 | $2.00 → $3.00 | Hold → Buy | Jefferies |
| 12/19/2024 | $12.00 → $2.00 | Buy → Hold | Jefferies |
| 3/8/2024 | $10.00 → $14.00 | Buy → Hold | Stifel |
| 12/8/2023 | $8.00 → $18.00 | Hold → Buy | Jefferies |
| 3/1/2022 | $60.00 → $36.00 | Buy | Stifel |
| 12/22/2021 | $65.00 → $25.00 | Buy → Hold | Jefferies |
| 9/30/2021 | $106.00 | Buy | Stifel |
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Canc
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit Format: One-on-one meetingsDate: February 24-25, 2026Location: Lake Tahoe, CA TD Cowen 46th Annual Health Care Conference Format: PresentationDate: March 3, 2026Time: 9:10 AM ESTL
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.
8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)
SCHEDULE 13G - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
SCHEDULE 13D/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl
Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Canc
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.
ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levels Phase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026 Cash runway expected into Q1 2027 to support key milestones, including ALX2004 initial safety data in 1H 2026, interim data for ASPEN-09-Breast Cancer in Q3 2026 Appointed Board Member Barbara Klencke, M.D.
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
Jefferies initiated coverage of ALX Oncology with a rating of Buy and set a new price target of $4.00
Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously
Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)